Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance
Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance
复制标题
丙酮酸激酶同工型 M2 (PKM2) 参与多发性骨髓瘤细胞增殖、粘附和化疗耐药
DOI：
10.1016/j.leukres.2015.09.019
复制
发表时间：
2015-12-01
影响因子：
2.7
通讯作者：
Cheng, Chun
中科院分区：
文献类型：
--
作者：
He, Yunhua;Wang, Yuchan;Cheng, Chun
Cell adhesion mediated drug resistance (CAM-DR) remains the major barrier in human multiple myeloma (MM) therapy. In the present study, we aimed at investigating the role of pyruvate kinase isoform M2 (PKM2) in MM CAM-DR. We determined that PKM2 expression was positively correlated with cell proliferation and knockdown of PKM2 contributed to the increased cell adhesion rate in MM. The enhancement in the adhesion of MM cells to fibronectin or the bone marrow stroma cell line HS-5 cells translated to an increased CAM-DR phenotype. Importantly, we showed that this CAM-DR phenotype was correlated with the phosphorylation of Akt and ERK in MM cells. Taken together, our data shed new light on the molecular mechanism of CAM-DR in MM, and targeting PKM2 may be a novel therapeutic approach for improving the effectiveness of chemotherapy in MM. (C) 2015 Published by Elsevier Ltd.
